Androgen Modulation of Coregulator Expression in Prostate Cancer Cells
Overview
Molecular Biology
Authors
Affiliations
Aberrant coregulator expression that occurs during prostate cancer (PCa) progression correlates with poor prognosis and aggressive disease. This has been attributed to the ability to regulate androgen receptor-mediated transcription. We have shown previously that the androgenic milieu regulates the expression of the coactivators p300 and FHL2, with severe consequences for PCa cell proliferation and androgen receptor transcriptional activity. To determine the extent of androgen dependency of coregulator genes, we designed a cDNA-mediated annealing, selection, extension, and ligation RNA profiling array that probes the expression of 186 coregulators. Using this assay, we demonstrated androgen control over approximately 30% of coregulator genes in PCa cells. For a subset of 15 functionally diverse coregulators, androgen regulation was confirmed using real-time RT-PCR and immunoblotting. The extent, dose dependency, and kinetics by which androgens affect coregulator expression differed widely, indicating diverse molecular mechanisms underlying these effects. Moreover, differences in coregulator expression were observed between isogenic androgen-dependent and castration-recurrent PCa cells. Small interfering RNA-mediated changes in coregulator expression had profound effects on cell proliferation, which were most pronounced in castration-recurrent cells. Taken together, our integrated approach combining expression profiling, characterization of androgen-dependent coregulator expression, and validation of the importance of altered coregulator expression for cell proliferation identified several potential novel therapeutic targets for PCa treatment.
Prakasam R, Bonadiman A, Andreotti R, Zuccaro E, Dalfovo D, Marchioretti C Nat Commun. 2023; 14(1):603.
PMID: 36746939 PMC: 9902531. DOI: 10.1038/s41467-023-36186-9.
Launonen K, Paakinaho V, Sigismondo G, Malinen M, Sironen R, Hartikainen J Oncogene. 2021; 40(27):4567-4579.
PMID: 34127815 PMC: 8266679. DOI: 10.1038/s41388-021-01887-2.
Lv S, Song Q, Chen G, Cheng E, Chen W, Cole R J Clin Invest. 2020; 131(4).
PMID: 33332287 PMC: 7880411. DOI: 10.1172/JCI141335.
Yong C, Moose D, Bannick N, Gutierrez W, Vanneste M, Svensson R PLoS One. 2020; 15(9):e0232807.
PMID: 32986721 PMC: 7521703. DOI: 10.1371/journal.pone.0232807.
FHL2 mediates podocyte Rac1 activation and foot process effacement in hypertensive nephropathy.
Li S, Chu P, Huang P, Hsieh T, Susztak K, Tarng D Sci Rep. 2019; 9(1):6693.
PMID: 31040292 PMC: 6491468. DOI: 10.1038/s41598-019-42328-1.